News Releases

-Genor BioPharma and RuiYi Collaborated Development Novel Therapeutic mAb gerilimzumab starts PhI

-Genor Biopharm is undertaking two CRO&CMO collaboration projects for mAb products

-Genor Biopharma successfully introduces new strategic investors

-Genor Biopharma filed Rituximab biosimilar IND application

-Genor Biopharma's Adalimumab biosimilar (GB232) started Phase I clinical trial in South Korea

-Genor Biopharma's Infliximab biosimilar got clinical trial approval from the CFDA

-Genor Biopharma's Bevacizumab biosimilar (GB222) IND application accepted by Shanghai CFDA

-Genor Biopharma's Adalimumab biosimilar (GB232/BCD-100) got clinical trial approval in S. Korea

-Genor Biopharma and BIOCND form partnership to develop mAb biosimilars for international market

-Genor BioPharma and RuiYi Collaborate on Development in China of RYI-008, a Novel Therapeutic mab

Weather Info
About Genor

Genor Biopharma Co. Ltd. was founded in December 2007. It is an innovation-driven international biopharmaceutical company, focusing on development and commercialization of therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Currently Genor has more than 10 products in pipeline, several of which have entered clinical stage. In December 2013, Genor was acquired by Walvax Biotechnology Co., Ltd (Walvax: 300142), a public listed biopharma in China.

Business Development

Genor Biopharma has several product in the clinical and preclinical stage (including biosimilar and innovative drugs). We are activily seeking collaboration partnerships to co-develop emerging market and EU/US markets.

If you are interested in such collaboration opportunities, please contact our business development department. We are sincerly looking forward to the partnership oportunites to enrich our pipeline, and t o accelerate product development  and commercialization.


Contact Us

Genor Biopharma Co., Ltd.

Building 3, 1690 Zhangheng Rd., Pudong, Shanghai, China 201203

Tel: +86 21 6069 0700 Ext. 55567

Fax: +86 21 6075 1991